Efficacy of a low-dose omeprazole-based triple-therapy regimen for Helicobacter pylori eradication independent of cytochrome P450 genotype: The Japanese MACH study

Clinical Drug Investigation

Volumn 25, Issue 5, 2005, Pages 293-305

  Kuwayama, Hajime ^a   Luk, Gordon ^a   Yoshida, Shunichi ^b   Nakamura, Takefumi ^c   Kubo, Mitsuhiko ^d   Uemura, Naomi ^e   Harasawa, Shigeru ^f   Kaise, Mitsuru ^g   Sanuki, Eiko ^h   Haruma, Ken ⁱ   Inoue, Masaki ⁱ   Shimatani, Tomohiko ⁱ   Mieno, Hiroshi ^j   Kawanishi, Masahiro ^k   Watanabe, Hidenobu ^l   Nakashima, Mituyoshi ^m   Nakazawa, Saburo ⁿ  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b Akashi Municipal Hospital   (Japan)

^c Kitano Hospital   (Japan)

^d OSAKA POLICE HOSPITAL   (Japan)

^e Kure Kyousai General Hospital   (Japan)

^f Saiseikai Kawaguchi General Hospital   (Japan)

^g Toshiba General Hospital   (Japan)

^h Saiseikai Hiroshima Hospital   (Japan)

ⁱ HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^j HIROSHIMA GENERAL HOSPITAL   (Japan)

^k Hiroshima Mitsubishi Hospital   (Japan)

^l NIIGATA UNIVERSITY   (Japan)

^m HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ Yamashita Hospital   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450; CYTOCHROME P450 2C19; OMEPRAZOLE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BITTER TASTE; BRONCHITIS; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMON COLD; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; FEMALE; FEVER; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL INFECTION; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; GENOTYPE; HEADACHE; HEARTBURN; HELICOBACTER PYLORI; HUMAN; JAPAN; LIVER DYSFUNCTION; LOOSE FECES; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEPTIC ULCER; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE RISK; REFLUX ESOPHAGITIS; REMISSION; REMISSION TIME CURVE; SLEEP DISORDER; STOMACH PAIN; TASTE DISORDER; TIME; TREATMENT FAILURE; ULCER HEALING; UPPER RESPIRATORY TRACT INFECTION;

EID: 20444406046     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525050-00002     Document Type: Article

References (26)

1. Van der Hulst RW, Rauws EA, Koycu B, et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology 1997; 113: 1082-6
2. Soll AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA 1996; 275: 622-9
3. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 15: 167-80
4. Peura D. Helicobacter pylori: rational management options. Am J Med 1998; 105: 42400
5. Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995; 9 Suppl. 2: 59-69
6. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994; 272: 65-9
7. Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996; 1: 138-44
8. Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 248-53
9. Zanten SJ, Bradette M, Farley A, et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 1999; 13: 289-95
10. Malfertheiner P, Bayerdorffer E, Diete U, et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999; 13: 703-12
11. Japanese Society of Helicobacter Research. The guideline for diagnosis and treatment of Helicobacter pylori infection [in Japanese]. Jpn J Helicobacter Res 2000; 2 (Suppl.): 2-12
12. Japanese Society of Helicobacter Research. The Guideline for diagnosis and treatment of Helicobacter pylori infection 2003 revision [in Japanese]. Jpn J Helicobacter Res 2003; 4 (Suppl.): 2-16
13. Unge P, Kimura K, Sipponen P, et al. Do Japanese and Swedish peptic ulcer patients respond differently to Helicobacter pylori eradication therapies and what are their histological features? Scand J Gastroenterol 2003; 38: 482-90
14. Janssen MJ, Van Oijen AH, Verbeek AL, et al. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Aliment Pharmacol Ther 2001; 15: 613-24
15. Furuta T, Shirai N, Sugimoto M, et al. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004; 5: 181-202
16. Sapone A, Vaira D, Trespidi S, et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Am J Gastroenterol 2003; 98: 1010-5
17. 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan. J Gastroenterol 1998; 33: 6-13
18. NCCLS. Performance standards for antimicrobial susceptibility testing ninth informational supplement. Pennsylvania: NCCLS, 1999: M100-S9
19. Committee on assessment of antimicrobial agents: Helicobacter pylori Committee. Establishment of breakpoint of clarithromycin (CAM) and amoxicillin (Amox) for Helicobacter pylori eradication. Tokyo: Japan Society of Chemotherapy, 2000
20. De Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46 (4): 594-8
21. Japanese Society of Gastroenterology. The guideline for clinical studies on Helicobacter pylori. 1995 [in Japanese]. Tokyo: The Japanese Society of Gastroenterology, 1999
22. Nakamura M, Spiller RC, Barrett DA, et al. Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy. Helicobacter 2003; 8: 294-9
23. Miwa H, Ohkura R, Murai T, et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection: comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999; 13: 741-6
24. Asaka M, Sugiyama T, Kato M, et al. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 2001; 6: 254-61
25. Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72: 453-60
26. Asaka M, Kato M, Sugiyama T, et al. Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J Gastroenterol 2003; 38: 339-47